SIGN 146: Cutaneous melanoma

Zusammenfassung

Cutaneous melanoma A national clinical guideline First published January 2017 Revised August 2023 Revised February 2025 SIGN14 6 Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2 ++ High-quality syste

Kerninformationen

R For ‘conditional’ recommendations on interventions that should be ‘considered’, the guideline development group is confident that the intervention will do more good than harm for most patients. The choice of intervention is therefore more likely to vary depending on a person’s values and prefere...

Cutaneous melanoma 2025. (SIGN publication no. 146). [February 2025]. Available from URL: http://www.sign.ac.uk This document is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence. This allows for the copy and redistribution of this document as lon...

In Scotland it is the fifth most common cancer in women and seventh in men. 1 In Scotland, between 2007 and 2018, the incidence of melanoma in adults has increased by 6%, but mortality rates have decreased by 10–19.1% between 2008 and 2018. 1 The primary risk factor for cutaneous melanoma is ex...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen